Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Shares Slide 9.3 Percent Despite 52-Percent Q1 Revenue Growth

This article has been corrected from a previous version. Adam Chazan does not cover Genaissance for Pacific Growth, and the reported cash burn rate of $3 million and total cash on hand were incomplete figures.


NEW YORK, May 3 (GenomeWeb News) - Shares in Genaissance sank more than 9.3 percent, or $.10, to $.98 in late-afternoon trading despite the company posting a 51-percent increase in total revenue and a 34-percent decline in net losses.


Total receipts for the three months ended March 31 increased to $5.6 million from $3.7 million year over year. Revenues from licensing and research were flat at $2.9 million, though receipts from lab services swelled to $2.7 million from $860,000 in the year-ago quarter.


Genaissance said it spent $3.3 million on R&D, down from $5 million during the first quarter 2004.


Net losses in the period fell to $3.1 million, or $.09 per basic share, from $4.7 million, or $.21 per basic share, year over year.


Genaissance said it had around $5.9 million in cash and equivalents as of March 31.


"There is also $1.3 million of non-cash charges, so the cash loss is only $1.7 million [per quarter]. And we added $2 million of cash at the end of the quarter," Ben Kaplan, the company's CFO, told GenomeWeb News. Genaissance's current cash on hand is about $8 million, said Kaplan.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.